Growth Company Investor - Stock market recommendations on AIM and small cap companies

10 February 2016

Share Recommendations

05/02/16

A strong order book keeps this building products company on the buy list 

03/02/16

Time for this agri-tech specialist to deliver on its promise

01/02/16

Learning to grow fast

01/02/16

A cheap rating and strategic change make this media stock a buy 

19/01/16

This retailer is back on the front foot and offers a huge yield 

18/01/16

Positive Christmas trading underpins this recent buy tip

15/01/16

A shrewd deal results in upgrades for this existing buy recommendation

14/01/16

Take a gamble on this very cheap gaming stock and earn 7 percent while you wait

12/01/16

This innovative battery technology company is getting close to its first product launch.

07/01/16

Strong trading and upgrades leave this machinery stock looking very attractive

07/01/16

Upgrades fuel further gains for this HR consultant  

04/01/16

Profit upgrades, a strategic review, and a modest valuation make this medical device stock a Buy 

Cash Shells 2015

Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. Order your copy today

 

Superb investment toolkit for private investors

SharePad is the new web-based service from ShareScope. Easier to use and more powerful. Perfect for tablets, Macs and Windows PC. Covers ALL your investment requirements.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Share recommendations and small-cap stock picks

Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.

What Investment magazine: save 45% on the shop price

Be the first to receive our independent analysis and research, designed to help you generate more wealth for you and your family over the long term. Subscribe and save.

Popular Recommendations

Latest News

Diurnal to profit from orphan drugs

Drug developer Diurnal (AIM: DNL) joined AIM a couple of days before Christmas. It already has one product in final phase III clinical trials and another due to start them shortly. So revenue generation at Diurnal should be a lot closer than at many junior biotechs. If all goes according to plan lead product Infacort should hit the market in 2018.

Forbidden focuses on selling

Forbidden Technologies (AIM: FBT) has been around a long time but has failed to generate much in the way of revenues, despite having a product that sounds like it should be a winner. There were board changes last year and new CEO Aziz Musa is shifting resources towards selling and away from technological development. This has to be the right strategy and we should find out if it’s working as this year unfolds.

Wash those nits right out of your hair!

Tyratech (AIM: TYRU) offers a compelling product proposition. Controlling bugs and parasites using conventional pesticides is both harmful to the environment and ineffective. Over the years insects have built up resistance to many of the chemicals used to kill them. So Tyratech’s natural products are not only safer but also a lot more effective than the competition. 

Angling for a cancer breakthrough

Results from medical device manufacturer Angle (AIM: AGL) showed its innovative Parsortix system to be nicely on track. The first commercial sales for research use have just been made and three leading cancer centres are moving forward with trials that will support its clinical use in the diagnosis of ovarian cancer.

2016 Quoted Company Award Winners announced

The 12th annual Grant Thornton Quoted Company Awards took place this week at the Natural History Museum in London. This prestigious event is organised by Growth Company Investor and is a celebration of the success and achievements of the UK’s smaller company sector. We published the shortlisted nominees for each award category earlier in January; so read on to see who the winners were...

Plexus hammered by oil industry shutdown

In the middle of 2014 Plexus (AIM: POS) was riding high with a share price of 320p giving the company a market value of £270 million. Today’s profit warning has seen the shares slump 40 per cent to just 73p, valuing Plexus at a mere £65 million. As an engineering company selling mainly into the oil industry, we shouldn’t be too surprised by downgrades. But the severity is startling.

More News